Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Bristol Gate Capital Partners Inc.

Bristol Gate Capital Partners Inc. lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 160,304 shares of the medical research company’s stock after selling 3,745 shares during the period. Thermo Fisher Scientific comprises 4.1% of Bristol Gate Capital Partners Inc.’s portfolio, making the stock its 18th largest holding. Bristol Gate Capital Partners Inc.’s holdings in Thermo Fisher Scientific were worth $83,395,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Norges Bank acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $3,149,754,000. Proficio Capital Partners LLC raised its stake in Thermo Fisher Scientific by 68,617.0% during the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company’s stock valued at $396,810,000 after acquiring an additional 761,649 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $377,901,000. Grantham Mayo Van Otterloo & Co. LLC increased its stake in shares of Thermo Fisher Scientific by 140.7% during the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company’s stock valued at $569,062,000 after acquiring an additional 639,467 shares during the period. Finally, Lindsell Train Ltd bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $211,858,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $437.71 on Monday. Thermo Fisher Scientific Inc. has a 1-year low of $411.12 and a 1-year high of $627.88. The stock has a market capitalization of $165.13 billion, a P/E ratio of 26.48, a P/E/G ratio of 2.99 and a beta of 0.86. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $532.01 and a two-hundred day moving average price of $547.03.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.39%. Thermo Fisher Scientific’s payout ratio is 10.41%.

Wall Street Analyst Weigh In

Several analysts recently commented on TMO shares. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. UBS Group lifted their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Wells Fargo & Company raised their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Scotiabank upped their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research report on Monday, February 3rd. Finally, Citigroup reduced their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.